Skip to content
Does This Drug Represent “A Paradigm Shift for Small Molecule Drug Development?” episode artwork

Sep 4, 2024 28 min

Does This Drug Represent “A Paradigm Shift for Small Molecule Drug Development?”

from The Bio Report Hosted by Levine Media Group

NAMPT is a critical enzyme that regulates how cells use energy. It can also play an important role in the ability of cancer cells to survive, grow, and spread. While it’s been recognized as a potential target to treat certain cancers, developing NAMPT inhibitors have been challenging because they can disrupt energy metabolism in healthy cells. Remedy Plan Therapeutics believes it’s overcome the challenges of NAMPT inhibition by a unique mechanism of action that can avoid the problem of toxicity. We spoke to Greg Crimmins, founder and CEO of Remedy Plan Therapeutics, about the role of NAMPT in cancer, the challenges of developing NAMPT inhibitors without toxicity, and why he believes the company has solved the problem.

Episode details come from the podcast's RSS feed.

Embed this episode

Greg Crimmins, founder and CEO of Remedy Plan Therapeutics, discusses the role of NAMPT in cancer, the challenges of developing NAMPT inhibitors without toxicity, and why he believes the company has solved the problem.

Ready to play

Does This Drug Represent “A Paradigm Shift for Small Molecule Drug Development?”

0:00 28:01

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of The Bio Report?

This episode is 28 minutes long.

When was this The Bio Report episode published?

This episode was published on September 4, 2024.

Can I download this The Bio Report episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.